RT Journal Article
SR Electronic
T1 Efficacy and tolerability of bevacizumab in patients with severe Covid -19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.26.20159756
DO 10.1101/2020.07.26.20159756
A1 Jiaojiao Pang
A1 Feng Xu
A1 Gianmarco Aondio
A1 Yu Li
A1 Alberto Fumagalli
A1 Ming Lu
A1 Giuseppe Valmadre
A1 Jie Wei
A1 Yuan Bian
A1 Margherita Canesi
A1 Giovanni Damiani
A1 Yuan Zhang
A1 Dexin Yu
A1 Jun Chen
A1 Xiang Ji
A1 Wenhai Sui
A1 Bailu Wang
A1 Shuo Wu
A1 Attila Kovacs
A1 Miriam Revera
A1 Hao Wang
A1 Ying Zhang
A1 Yuguo Chen
A1 Yihai Cao
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.26.20159756.abstract
AB On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesized that the anti-VEGF drug bevacizumab might be beneficial for treating Covid-19 patients. We recruited 26 patients from 2-centers (China and Italy) with confirmed severe Covid-19, with respiratory rate ≥ 30 times/min, oxygen saturation ≤ 93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100mmHg and ≤ 300 mmHg, and diffuse pneumonia confirmed by chest radiological imaging. This trial was conducted from Feb 15 to April 5, 2020, and followed up for 28 days. Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age, 62 years, 20 [77%] males), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], p<0.001; day 7, 111.0 [85.0,165.0], p<0.001). By day 28, 24 (92%) patients showed improvement in oxygen-support status, 17 (65%) patients were discharged, and none showed worsen oxygen-support status nor died. Significant reduction of lesion areas and ratios were shown in chest CT or X-ray analysis within 7 days. Of 14 patients with fever, body temperature normalized within 72 hours in 13 (93%) patients. Lymphocyte counts in peripheral blood were significantly increased and CRP levels were markedly decreased as shown in available data. Our findings suggested bevacizumab plus standard care was highly beneficial for treating patients with severe Covid-19. Clinical efficacy of bevacizumab warrants double blind, randomized, placebo-controlled trials.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04275414, URL: https://clinicaltrials.gov/ct2/show/NCT04275414.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov NCT04275414Funding StatementThis study was supported by grants from National Key R#x00EF;#x00BC;†D Program of China (2020YFC0846600) and Shandong Provincial Key R#x00EF;#x00BC;†D Program (2020SFXGFY03).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the ethics committees of Qilu Hospital of Shandong University, Renmin Hospital of Wuhan University, and Italia Hospital S.p.A. Ospedale Generale di Zona Moriggia - Pelascini, Gravedona ed Uniti (CO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data related to the results in this article will be available one year after publishment.